

Sigurdis Haraldsdottir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4813489/publications.pdf>

Version: 2024-02-01

43
papers

1,445
citations

361413
20
h-index

330143
37
g-index

44
all docs

44
docs citations

44
times ranked

2893
citing authors

#	ARTICLE	IF	CITATIONS
1	Universal tumor screening in a population with MSH6- and PMS2-associated Lynch syndrome. <i>Genetics in Medicine</i> , 2022, , .	2.4	1
2	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e236-e247.	2.9	22
3	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 668-675.	3.7	20
4	Profiling diverse sequence tandem repeats in colorectal cancer reveals co-occurrence of microsatellite and chromosomal instability involving Chromosome 8. <i>Genome Medicine</i> , 2021, 13, 145.	8.2	6
5	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	10.7	48
6	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa054.	2.9	6
7	An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005140.	1.2	1
8	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	3.7	30
9	Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz095.	2.9	15
10	Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000299.	2.7	9
11	Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 605-615.	1.4	4
12	Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. <i>Journal of Medical Genetics</i> , 2019, 56, 462-470.	3.2	61
13	Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 573-580.	1.3	26
14	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1032-1041.	4.9	191
15	Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. <i>Human Pathology</i> , 2018, 78, 125-130.	2.0	28
16	Management of Borderline Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1155-1174.	0.8	48
17	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-19.	3.0	2
18	Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1035-1040.	4.9	24

#	ARTICLE	IF	CITATIONS
19	Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants. <i>Oncologist</i> , 2018, 23, 1395-1400.	3.7	8
20	The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 972-975.	1.5	2
21	Promising New Agents for Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 29.	3.0	46
22	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017, 8, 14755.	12.8	96
23	Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy?. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 419-428.	0.5	1
24	Microsatellite Instability Testing Using Next-Generation Sequencing Data and Therapy Implications. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	3.0	8
25	Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome-associated Neoplasms. <i>American Journal of Clinical Pathology</i> , 2016, 146, 50-56.	0.7	24
26	Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. <i>Familial Cancer</i> , 2016, 15, 253-260.	1.9	36
27	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. <i>Gastroenterology</i> , 2016, 151, 440-447.e1.	1.3	36
28	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016, 18, 863-868.	2.4	30
29	Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy. <i>JAMA Dermatology</i> , 2016, 152, 587.	4.1	11
30	Circulating tumor markers in patients with neuroendocrine tumors – a clinical perspective. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 89-99.	0.4	5
31	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	2.4	88
32	An update on clinical trials of targeted therapies in thyroid cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 36-44.	2.4	24
33	New era for treatment in differentiated thyroid cancer. <i>Lancet, The</i> , 2014, 384, 286-288.	13.7	10
34	How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 372-379.	0.5	6
35	Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations. <i>Gastroenterology</i> , 2014, 147, 1308-1316.e1.	1.3	328
36	Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 419-419.	1.6	0

#	ARTICLE	IF	CITATIONS
37	A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. Journal of Clinical Oncology, 2014, 32, TPS2628-TPS2628.	1.6	0
38	Case of Sorafenib-Induced Thyroid Storm. Journal of Clinical Oncology, 2013, 31, e262-e264.	1.6	22
39	What is the optimal neo-adjuvant treatment for liver metastasis?. Therapeutic Advances in Medical Oncology, 2013, 5, 221-234.	3.2	12
40	Integrating anti-EGFR therapies in metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 285-98.	1.4	20
41	Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population. European Journal of Radiology, 2010, 76, 188-194.	2.6	23
42	Clinical evaluation and stress test have limited value in the diagnosis of in-stent restenosis. Scandinavian Cardiovascular Journal, 2009, 43, 402-407.	1.2	3
43	Anti-Proliferative Effects of Lichen-Derived Lipxygenase Inhibitors on Twelve Human Cancer Cell Lines of Different Tissue Origin in vitro. Planta Medica, 2004, 70, 1098-1100.	1.3	63